title: Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
abstract: S-1 is a novel, oral fluoropyrimidine and a known radiosensitizer. We conducted a phase I trial to establish a schedule of S-1/irinotecan with standard pelvic radiotherapy as a preoperative treatment of locally advanced rectal cancer. Our findings suggest that this new combination is feasible and well tolerable.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Choi
authors.forename: Nam-Kyu
authors.initials: NK
authors.lastname: Kim
authors.forename: Ki Chang
authors.initials: KC
authors.lastname: Keum
authors.forename: Seong Ha
authors.initials: SH
authors.lastname: Cheon
authors.forename: Sang Jun
authors.initials: SJ
authors.lastname: Shin
authors.forename: Seung Hyuk
authors.initials: SH
authors.lastname: Baik
authors.forename: Jae Hee
authors.initials: JH
authors.lastname: Choen
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Rha
authors.forename: Jae Kyung
authors.initials: JK
authors.lastname: Roh
authors.forename: Hei-Cheul
authors.initials: HC
authors.lastname: Jeung
authors.forename: Hyun Cheol
authors.initials: HC
authors.lastname: Chung
authors.forename: Joong Bae
authors.initials: JB
authors.lastname: Ahn
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011838:Radiation-Sensitizing Agents; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin